2023 World Conference on Lung Cancer (Posters)-EP12.01. Anlotinib Combined with Osimertinib Reverses Acquired Osimertinib Resistance in NSCLC by Targeting the c-MET/MYC/AXL Axis

EP12.01. Anlotinib Combined with Osimertinib Reverses Acquired Osimertinib Resistance in NSCLC by Targeting the c-MET/MYC/AXL Axis - PDF(Slides)

Back to course

Pdf Summary

A study conducted by researchers at Nanjing Medical University investigated the potential of combining anlotinib with osimertinib to reverse acquired osimertinib resistance in non-small-cell lung cancer (NSCLC) patients with EGFR mutations. Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has shown improved survival rates in NSCLC patients. However, drug resistance limits its efficacy. <br /><br />The researchers conducted in vitro and in vivo experiments using osimertinib-resistant NSCLC cells to examine the effects of combining anlotinib with osimertinib. They found that the combination treatment was able to overcome osimertinib resistance and demonstrated synergistic anti-tumor effects in NSCLC cells. They also identified the c-MET/MYC/AXL axis as the target of this combination therapy. <br /><br />AXL was found to confer resistance to osimertinib, while anlotinib showed enhanced anti-tumor efficacy by inhibiting AXL in NSCLC cell lines. The researchers discovered that MYC binds to the promoter of AXL, promoting its transcription, and demonstrated that the combination treatment inactivated the c-MET/MYC/AXL axis in NSCLC. <br /><br />Overall, the study confirmed that combining anlotinib with osimertinib can effectively reverse acquired osimertinib resistance in NSCLC patients with EGFR mutations. This combination therapy targets the c-MET/MYC/AXL axis, providing potential clinical application for treating NSCLC patients who develop resistance to osimertinib. Further research is needed to validate these findings and explore the clinical implications of this combination therapy.

Asset Subtitle

Zhaoxia Wang

Meta Tag

Speaker Zhaoxia Wang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Nanjing Medical University

anlotinib

osimertinib

acquired osimertinib resistance

non-small-cell lung cancer

NSCLC

EGFR mutations

epidermal growth factor receptor tyrosine kinase inhibitor

in vitro experiments

in vivo experiments